Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Scotoma Reduction in AMD Patients Treated With Ranibizumab (SALVAGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00467935
Recruitment Status : Completed
First Posted : May 1, 2007
Last Update Posted : July 29, 2011
Information provided by:
Retina Research Foundation

Brief Summary:
This is a trial aimed at patients with advanced wet macular degeneration and macular scarring treated wiht intravitreal injections of Lucentis.

Condition or disease Intervention/treatment Phase
Macular Degeneration Drug: intravitreal injection Lucentis (ranibizumab) Phase 1 Phase 2

Detailed Description:
Patients with severe wet macular degeneration and scarring in the center of the retina may benefit from treatment if the size of the blind spot is reduced wiht injections of Lucentis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study to Evaluate Scotoma Reduction in And Limited Visual Acuity in aGe Related Macular Degeneration Patients Treated With Intravitreal Lucentis
Study Start Date : March 2007
Actual Primary Completion Date : November 2007
Actual Study Completion Date : November 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Intervention Details:
  • Drug: intravitreal injection Lucentis (ranibizumab)
    intravitreal injection Lucentis (ranibizumab)

Primary Outcome Measures :
  1. scotoma reduction [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. improved visual function [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • BCVA < 20/320
  • Disciform macular degeneration wiht exudation

Exclusion Criteria:

  • Non-amd CNV

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00467935

Layout table for location information
United States, New York
Retina Research Center
Slingerlands, New York, United States, 12159
Sponsors and Collaborators
Retina Research Foundation
Layout table for investigator information
Principal Investigator: Paul M Beer, MD Retina Research Foundation

Additional Information:
Layout table for additonal information
Responsible Party: Paul Beer, MD, Retina Consultants, PLLC Identifier: NCT00467935    
Other Study ID Numbers: FVF3933
First Posted: May 1, 2007    Key Record Dates
Last Update Posted: July 29, 2011
Last Verified: July 2011
Keywords provided by Retina Research Foundation:
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents